A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors (NCT05244551)
A Phase 1, Open-Label Study of ABSK061 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This is an open-label phase 1 study with expansion. The study will start with a dose escalation of single-agent ABSK061 administered in repeated 28-day cycles in patients with advanced solid tumors to evaluate safety and tolerability. The expansion part will investigate oral ABSK061 at the recommended dose for expansion (RDE) to further evaluate safety and tolerability among selected tumor types. Preliminary antitumor activity will also be assessed.
Who can join: Review the eligibility criteria below.
Location: Mary Crowley Cancer Research — Dallas, Texas
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (22 Sites)
- Mary Crowley Cancer Research — Dallas, Texas
- Yuan LU — Shanghai, Abbisko Therapeutics Co., Ltd. 12B Floor, Building 1, Lane 515
- The First Affiliated Hospital of Bengbu Medical College — Bengbu, Anhui
- Cancer Hospital Chinese Academy of Medical Sciences — Beijing, Beijing Municipality
- Chongqing Daping Hospital — Chongqing, Chongqing Municipality
- Fujian Cancer Hospital — Fuzhou, Fujian
- Zhejiang Cancer Hospital — Hangzhou, Gongshu District
- Sun Yat-sen Memorial Hospital/ the Second Affiliated Hospital of Sun Yat-sen University — Guanzhou, Guangdong
- Harbin Medical University Cancer Hospital — Harbin, Heilongjiang
- Henan Cancer Hospital — Zhengzhou, Henan
- The First Affiliated Hospital of Zhengzhou University — Zhengzhou, Henan
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology — Wuhan, Hubei
- The Affiliated Hospital of Inner Mongolia Medical University — Hohhot, Inner Mongolia
- Xuzhou Center Hospital — Xuzhou, Jiangsu
- First Hospital of Jilin University — Changchun, Jilin
- JILIN Cancer Hospital — Changchun, Jilin
- Yunnan Cancer Hospital — Yunnan, Kunming
- Liaoning Province Cancer Hospital — Shenyang, Liaoning
- The First Hospital of China Medical University — Shenyang, Liaoning
- Shanghai Chest Hospital — Shanghai, Shanghai Municipality
- Chongqing University Cancer Hospital — Chongqing, Sichuan
- The Second Affiliated Hospital Zhejiang University School of Medicine — Hanzhou, Zhejiang
📞 Contact the Study Coordinator
Phone: +86 21 68910052
Email: clinical@abbisko.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumor
- A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors — Houston, Texas
- A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer — Middletown, New Jersey
- A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer — Basking Ridge, New Jersey
- Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors — Chicago, Illinois
- A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors — New York, New York
- Concurrent Azeliragon With Craniospinal Irradiation — New York, New York
Explore by condition: All Solid Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.